We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




Majority of Patients Taking Blood-Thinners Given Wrong Dose

By HospiMedica International staff writers
Posted on 19 Nov 2012
A new study suggests that approximately 75% of patients taking two common blood-thinning drugs may be receiving the wrong dosage levels.

Researchers at the Intermountain Medical Center Heart Institute (Murray, UT, USA) conducted a study involving 521 patients receiving P2Y12 inhibitor therapy with either clopidogrel or prasugrel. More...
To ascertain if the patients were receiving the correct dosage of their prescribed medication, they conducted a blood-clotting test using the VerifyNow platelet function assay, as measured by P2Y12 reaction units (PRU). Guidelines for the use of platelet-function testing target a PRU of 100-200 and recommend changing medication dosing or type to reach this target.

The researcher found that based on PRU assays, 50% of the patients taking clopidogrel were getting too little of the drug to prevent clotting most effectively while 25% were getting too much; only 25% were getting an accurate dose. Regarding prasugrel, 50% were getting too much of the drug, which could lead to dangerous bleeding while 25% were getting too little; again, only 25% were getting the appropriate dose. The researchers also found that none of the baseline clinical variables of age, sex, hypertension, hyperlipidemia, heart failure, renal failure, prior cardiac history, or other nonplatelet related medications is predictive of PRU results. The study was presented at the American Heart Association (AHA) Scientific Sessions, held during November 2012 in Los Angeles (CA, USA).

“We showed that by performing a simple blood test to see whether or not the blood is clotting properly, we can determine whether patients are getting an appropriate, individualized dose of the medications. The test is easy to perform, but not widely used,” said lead author and study presenter cardiologist Brent Muhlestein, MD. “There's a sweet spot, an appropriate range for each patient. But we found that not many people are falling into that range.”

The VerifyNow System, a product of Accumetrics (San Diego, CA, USA) measures platelet reactivity by the rate and extent of light changes in whole blood as platelets aggregate over time, in response to agonists that are specific to various antiplatelet medications. Within the test device wells, the instrument measures the increase in light transmittance over time. A patient’s blood sample that exhibits inhibited platelet function produces low light transmittance, whereas a sample with normal platelet function produces high light transmittance. The system is based on the principles of optical aggregometry.

Related Links:
Intermountain Medical Center Heart Institute
Accumetrics


Gold Member
STI Test
Vivalytic Sexually Transmitted Infection (STI) Array
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
LED Surgical Lamp
ACEMST35/57
Syringes
Prefilled Saline Flush Syringes
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Surgical Techniques

view channel
Image: The AI-based approach identifies lipid regions matched well with histopathology results (Photo courtesy of Hyeong Soo Nam/KAIST)

AI-Based OCT Image Analysis Identifies High-Risk Plaques in Coronary Arteries

Lipid-rich plaques inside coronary arteries are strongly associated with heart attacks and other major cardiac events. While optical coherence tomography (OCT) provides detailed images of vessel structure... Read more

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.